AgomAb Therapeutics (NASDAQ:AGMB) Shares Down 4.5% – Should You Sell?

AgomAb Therapeutics NV (NASDAQ:AGMB) shares fell 4.5% during trading on Wednesday . The company traded as low as $15.14 and last traded at $15.19. 64,273 shares were traded during trading, a decline of 64% from the average session volume of 177,089 shares. The stock had previously closed at $15.90.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Wall Street Zen upgraded AgomAb Therapeutics to a “hold” rating in a report on Tuesday, February 17th. Zacks Research raised shares of AgomAb Therapeutics to a “hold” rating in a research report on Wednesday. JPMorgan Chase & Co. initiated coverage on shares of AgomAb Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $32.00 target price on the stock. Morgan Stanley began coverage on shares of AgomAb Therapeutics in a report on Tuesday. They set an “overweight” rating and a $28.00 price target for the company. Finally, Leerink Partners began coverage on shares of AgomAb Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $36.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $32.00.

AgomAb Therapeutics Price Performance

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.